Elotuzumab
(Anti-human SLAMF7 mAb, human IgG1-Kappa; HuLuc63)
Catalog No.: PC-Ab1097Not For Human Use, Lab Use Only.
Elotuzumab (HuLuc63) is a humanized mAb that targets the cell surface adhesion molecule CS1, which is selectively expressed on more than 95% of plasma cells and has little to no expression on normal tissues. Elotuzumab binds to CS1 on MM cells and NK cells recognize the Fc region of antibody by CD16 and thus mediate ADCC (Antibody-dependent cell-mediated cytotoxicity) against MM cells. In addition, binding of Elotuzumab on CS1 on the NK cells activate natural cytotoxicity of NK cells. Activation
Elotuzumab (HuLuc63) is a humanized mAb that targets the cell surface adhesion molecule CS1, which is selectively expressed on more than 95% of plasma cells and has little to no expression on normal tissues. Elotuzumab binds to CS1 on MM cells and NK cells recognize the Fc region of antibody by CD16 and thus mediate ADCC (Antibody-dependent cell-mediated cytotoxicity) against MM cells. In addition, binding of Elotuzumab on CS1 on the NK cells activate natural cytotoxicity of NK cells. Activation of NK cells induce the secretion of IFN-γ and this. Elotuzumab has been approved in combination with lenalidomide and dexamethasone (ELd) for relapsed/refractory multiple myeloma (MM).
Physicochemical Properties
M.Wt
Formula
Human IgG1-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
